Large cell carcinoma of the lung medical therapy: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Aditya Ganti (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
11,402 edits
Aditya Ganti (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
11,402 edits
Line 15: Line 15:
[[Image:Stage I.jpg|center|600px|]]
[[Image:Stage I.jpg|center|600px|]]
*Chemotherapy treatments for large  cell carcinoma of the lung, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref><ref name="pmid4042022">{{cite journal |vauthors=Ishii K, Ishii N, Shigenobu K, Kasuya Y |title=Acetylcholine supersensitivity in the rat heart produced by neonatal sympathectomy |journal=Can. J. Physiol. Pharmacol. |volume=63 |issue=7 |pages=898–9 |year=1985 |pmid=4042022 |doi= |url=}}</ref><ref name="wikip">Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330</ref>
*Chemotherapy treatments for large  cell carcinoma of the lung, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref><ref name="pmid4042022">{{cite journal |vauthors=Ishii K, Ishii N, Shigenobu K, Kasuya Y |title=Acetylcholine supersensitivity in the rat heart produced by neonatal sympathectomy |journal=Can. J. Physiol. Pharmacol. |volume=63 |issue=7 |pages=898–9 |year=1985 |pmid=4042022 |doi= |url=}}</ref><ref name="wikip">Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330</ref>
====Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy<ref>http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf</ref>====
*Cisplatin 50 mg/m2 days 1 and 8 AND [[vinorelbine]] 25 mg/m2 days 1, 8, 15, 22, every 28 days for 4 cycles
*Cisplatin 100 mg/m2 day 1 AND vinorelbine 30 mg/m2 days 1, 8, 15, 22, every 28 days for 4 cycles
*Cisplatin 75-80 mg/m2 day 1 AND vinorelbine 25-30 mg/m2 days 1 + 8, every 21 days for 4 cycles
*[[Cisplatin]] 100 mg/m2 day 1 AND etoposide 100 mg/m2 days 1-3, every 28 days for 4 cycles
*Cisplatin 80 mg/m2 days 1, 22, 43, 64 AND vinblastine 4 mg/m2 days 1, 8, 15, 22, 29 then every 2 wks after day 43, every 21 days for 4 cycles
*Cisplatin 75 mg/m2 day 1 AND gemcitabine 1250 mg/m2 days 1, 8, every 21 days for 4 cycles
*Cisplatin 75 mg/m2 day 1 AND [[docetaxel]] 75 mg/m2 day 1, every 21 days for 4 cycles
*Cisplatin 75 mg/m2 day 1 AND pemetrexed 500 mg/m2 day 1 for nonsquamous (without specific histologic subtype), every 21 days for 4 cycles
====Chemotherapy Regimens for Patients with Comorbidities or Patients Not Able to Tolerate Cisplatin<ref>http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf</ref>====
*Paclitaxel 200 mg/m2 day 1, carboplatin AUC 6 day 1, every 21 days
====Concurrent Chemotherapy and Radiation Therapy Regimens<ref>http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf</ref>====
*Cisplatin 50 mg/m2 on days 1, 8, 29, and 36 AND etoposide 50 mg/m2 days 1-5, 29-33 WITH concurrent thoracic radiation therapy
*Cisplatin 100 mg/m2 days 1 and 29 AND vinblastine 5 mg/m2/weekly x 5 WITH concurrent thoracic radiation therapy
*Carboplatin AUC 5 on day 1 AND pemetrexed 500 mg/m2 on day 1 every 21 days for 4 cycles WITH concurrent thoracic radiation therapy
*Cisplatin 75 mg/m2 on day 1 AND [[pemetrexed]] 500 mg/m2 on day 1 every 21 days for 3 cycles WITH concurrent thoracic radiation therapy
====Sequential Chemotherapy and Radiation Therapy Regimens<ref>http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf</ref>====
*Cisplatin 100 mg/m2 on days 1 and 29 AND [[vinblastine]] 5 mg/m2/weekly on days 1, 8, 15, 22, and 29 FOLLOWED by radiation therapy
*Paclitaxel 200 mg/m2 over 3 hours on day 1 AND carboplatin AUC 6 over 60 minutes on day 1 every 3 weeks for 2 cycles FOLLOWED by thoracic radiation therapy
====Concurrent Chemotherapy and Radiation Therapy Followed by Chemotherapy<ref>http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf</ref>====
*[[Paclitaxel]] 45-50 mg/m2 weekly AND carboplatin AUC 2 WITH concurrent thoracic radiation therapy FOLLOWED by 2 cycles of paclitaxel 200 mg/m2 and carboplatin AUC 6
*Cisplatin 50 mg/m2 on days 1, 8, 29, and 36 AND etoposide 50 mg/m2 days 1-5, 29-33 WITH concurrent thoracic radiation therapy FOLLOWED by cisplatin 50 mg/m2 and etoposide 50 mg/m2 x 2
:*[[Paclitaxel]]  
:*[[Paclitaxel]]  
:*[[Cisplatin]]  
:*[[Cisplatin]]  

Revision as of 22:42, 2 March 2018

Large Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Large Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Large cell carcinoma of the lung medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Large cell carcinoma of the lung medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Large cell carcinoma of the lung medical therapy

CDC on Large cell carcinoma of the lung medical therapy

Large cell carcinoma of the lung medical therapy in the news

Blogs on Large cell carcinoma of the lung medical therapy

Directions to Hospitals Treating Large cell carcinoma of the lung

Risk calculators and risk factors for Large cell carcinoma of the lung medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with large cell carcinoma of the lung. Chemotherapy may be required upon histological subtype of large cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for large cell carcinoma of the lung is neoadjuvant chemotherapy or adjuvant chemotherapy, followed or preceded by surgical resection. There is no consensus on treatment in patients with large cell lung neuroendocrine carcinoma. Commonly used chemotherapeutic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.

Medical Therapy

  • Initial chemotherapy for patients with large cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging.
  • Chemotherapy for patients with large cell carcinoma of the lung, is divided into 2 main types: specific-inhibitor therapy (usually indicated with the presence of a genetic mutation) and platinum-based chemotherapy ( usually indicated with the absence of a genetic mutation)
  • Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with large cell carcinoma of the lung
  • Erlotinib is the first-line treatment for patients with large cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
  • Chemotherapy treatments for large cell carcinoma of the lung, include:[1][2][3]

Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy[4]

  • Cisplatin 50 mg/m2 days 1 and 8 AND vinorelbine 25 mg/m2 days 1, 8, 15, 22, every 28 days for 4 cycles
  • Cisplatin 100 mg/m2 day 1 AND vinorelbine 30 mg/m2 days 1, 8, 15, 22, every 28 days for 4 cycles
  • Cisplatin 75-80 mg/m2 day 1 AND vinorelbine 25-30 mg/m2 days 1 + 8, every 21 days for 4 cycles
  • Cisplatin 100 mg/m2 day 1 AND etoposide 100 mg/m2 days 1-3, every 28 days for 4 cycles
  • Cisplatin 80 mg/m2 days 1, 22, 43, 64 AND vinblastine 4 mg/m2 days 1, 8, 15, 22, 29 then every 2 wks after day 43, every 21 days for 4 cycles
  • Cisplatin 75 mg/m2 day 1 AND gemcitabine 1250 mg/m2 days 1, 8, every 21 days for 4 cycles
  • Cisplatin 75 mg/m2 day 1 AND docetaxel 75 mg/m2 day 1, every 21 days for 4 cycles
  • Cisplatin 75 mg/m2 day 1 AND pemetrexed 500 mg/m2 day 1 for nonsquamous (without specific histologic subtype), every 21 days for 4 cycles

Chemotherapy Regimens for Patients with Comorbidities or Patients Not Able to Tolerate Cisplatin[5]

  • Paclitaxel 200 mg/m2 day 1, carboplatin AUC 6 day 1, every 21 days

Concurrent Chemotherapy and Radiation Therapy Regimens[6]

  • Cisplatin 50 mg/m2 on days 1, 8, 29, and 36 AND etoposide 50 mg/m2 days 1-5, 29-33 WITH concurrent thoracic radiation therapy
  • Cisplatin 100 mg/m2 days 1 and 29 AND vinblastine 5 mg/m2/weekly x 5 WITH concurrent thoracic radiation therapy
  • Carboplatin AUC 5 on day 1 AND pemetrexed 500 mg/m2 on day 1 every 21 days for 4 cycles WITH concurrent thoracic radiation therapy
  • Cisplatin 75 mg/m2 on day 1 AND pemetrexed 500 mg/m2 on day 1 every 21 days for 3 cycles WITH concurrent thoracic radiation therapy

Sequential Chemotherapy and Radiation Therapy Regimens[7]

  • Cisplatin 100 mg/m2 on days 1 and 29 AND vinblastine 5 mg/m2/weekly on days 1, 8, 15, 22, and 29 FOLLOWED by radiation therapy
  • Paclitaxel 200 mg/m2 over 3 hours on day 1 AND carboplatin AUC 6 over 60 minutes on day 1 every 3 weeks for 2 cycles FOLLOWED by thoracic radiation therapy

Concurrent Chemotherapy and Radiation Therapy Followed by Chemotherapy[8]

  • Paclitaxel 45-50 mg/m2 weekly AND carboplatin AUC 2 WITH concurrent thoracic radiation therapy FOLLOWED by 2 cycles of paclitaxel 200 mg/m2 and carboplatin AUC 6
  • Cisplatin 50 mg/m2 on days 1, 8, 29, and 36 AND etoposide 50 mg/m2 days 1-5, 29-33 WITH concurrent thoracic radiation therapy FOLLOWED by cisplatin 50 mg/m2 and etoposide 50 mg/m2 x 2
  • Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of large cell carcinoma of the lung
  • Platinum-based chemotherapy consists of four to six cycles
  • Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent
  • To see more information about mangnagment approach for non-small cell lung cancer click here
  • To see more information about the chemotherapeutic regimens in non-small cell lung cancer click here

Complications

  • Medical therapy complications for large cell carcinoma of the lung will depend on the chemotherapeutic agent.
  • Common chemotherapy complications, include:[1]
  • Platinum-based chemotherapy, the main dose-limiting side effect of cancer treatment with platinum compounds, include:
  • Other chemotherapeutic agent complications, include:
  • Side effects symptoms of chemotherapeutic agents, include:

References

  1. ↑ 1.0 1.1 Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899
  2. ↑ Ishii K, Ishii N, Shigenobu K, Kasuya Y (1985). "Acetylcholine supersensitivity in the rat heart produced by neonatal sympathectomy". Can. J. Physiol. Pharmacol. 63 (7): 898–9. PMID 4042022.
  3. ↑ Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330
  4. ↑ http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
  5. ↑ http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
  6. ↑ http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
  7. ↑ http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
  8. ↑ http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Large_cell_carcinoma_of_the_lung_medical_therapy&oldid=1451083"